SG/PUT/NOVO-NORDISK B/900/0.1/20.06.25 | Market Closed - Bid/Ask 14:14:16 2024-07-03 EDT | After market 15:05:59 | |||
| 1.28 EUR | +10.34% |
|
1.31 | +2.34% |
| Current month | +10.34% | ||
| 1 month | -14.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 1.28 | +10.34% |
| 24-07-02 | 1.16 | +7.41% |
| 24-07-01 | 1.08 | -6.90% |
| 24-06-28 | 1.16 | +2.65% |
| 24-06-27 | 1.13 | 0.00% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 02:14 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9CVZ |
| ISIN | DE000SU9CVZ3 |
| Date issued | 2024-02-14 |
| Strike | 900 kr |
| Maturity | 2025-06-20 (352 Days) |
| Parity | 10 : 1 |
| Emission price | 2.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.41 € |
|---|---|
| Lowest since issue | 1.02 € |
| Spread | 0.04 € |
| Spread % | 3.01% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Warrants
- Warrant
